Summary
Pseudomonas aeruginosa is the most common cause of morbidity and mortality in patients with cystic fibrosis. The pathogenesis of the fatal pulmonary infections it causes is multifactorial. A number of immunomodulatory strategies are currently being developed to improve the welfare of cystic fibrosis patients. The overall aims of these therapies are to: (a) attenuate the pathogenic effects of the bacterium’s immunoevasive arsenal and the host inflammatory response; (b) boost pulmonary immunity; (c) modify the host’s mucosal abnormalities.
The major and most promising strategies involve: (a) protease inhibitor therapy with α-antitrypsin, secretory leukoprotease inhibitor, or ICI 200800, a synthetic chloromethylketone antagonist; (b) anti-inflammatory therapy, using ibuprofen rather than prednisone; (c) immunomodulation of the activities of leukotriene B4, interleukins-1 and -8 or tumour necrosis factor-α (only experimental data are available); (d) hyperimmune immunoglobulin transfer; (e) vaccination with an anti-idiotype antibody mimicking the P. aeruginosa mucoid exopolysaccharide, or oral immunisation with mucoid P. aeruginosa antigens (only experimental data are available); (f) treatment with aerosolised recombinant human deoxyribonuclease-I (DNase) and other mucolytic agents.
To date, only protease inhibitors, ibuprofen and DNase are available (or will be available in the very near future) to the physician caring for patients with cystic fibrosis. Until curative treatment becomes feasible, clinical trials investigating alternative immunotherapies must receive a high priority on the list of strategies that need to be developed in order to improve the prognosis of patients with cystic fibrosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rommens JM, Iannuzzi MC, Kerem B-S, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059–65
Riordan JR, Rommens JM, Kerem B-S, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066–73
Kerem B-S, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073–80
Alton EW, Middleton PG, Caplen NJ, et al. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genet 1993; 5: 135–42
Hoiby N, Koch C. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax 1990; 45: 881–4
Fick RBJ, Stillwell PC. Controversies in the management of pulmonary disease due to cystic fibrosis. Chest 1989; 95: 1319–27
Holsclaw DSJ. Cystic fibrosis and pulmonary involvement from multiple perspectives. Semin Respir Infect 1992; 7: 141–50
Thompson AB, Smits WL, Fick RBJ. Immunomodulatory therapies for cystic fibrosis. Semin Respir Infect 1992; 7: 218–26
Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774–9
Lloyd-Still JD, Wessel HU. Advances and controversies in cystic fibrosis. Semin Respir Med 1990; 11: 197–210
Buret A, Cripps AW. The immunoevasive activities of Pseudomonas aeruginosa: relevance for cystic fibrosis. Am Rev Respir Dis 1993; 148: 793–805
Speert DP. Host defences in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa. Surv Synth Pathol Res 1985; 4: 14–33
Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4: 35–51
McGowan KL. The microbiology associated with cystic fibrosis. Clin Microbiol Newslett 1988; 10: 9–13
Novelli F, Giovarelli M, Reber-Liske R, et al. Blockade of physiologically secreted IFN-γ inhibits human T lymphocyte and natural killer cell activation. J Immunol 1991; 147: 1445–52
Pier GB. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis 1985; 151: 575–80
Fick RBJ, Sonoda F, Hornick DB. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway. Semin Respir Infect 1992; 7: 168–78
Lindsay CA, Bosso JA. Optimization of antibiotic therapy in cystic fibrosis patients. pharmacokinetic considerations. Clin Pharmacokinet 1993; 24: 496–506
Saiman L, Cacalano G, Gruenert D, et al. Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect Immun 1992; 60: 2808–14
Jiang C, Finkbeiner WE, Widdicombe JH, et al. Altered fluid transport across airway epithelium in cystic fibrosis. Science 1993; 262: 424–7
Barash J, Kiss B, Prince A, et al. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991; 352: 70–3
Saiman L, Prince A. Pseudomonas aeruginosa pili bind to asialo GM1 which is increased on the surface of cystic fibrosis epithelial cells. J Clin Invest 1993; 92: 1875–80
Girod de Bentzmann S, Pierrot D, Fuchey C, et al. Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus. Eur Resp J 1993; 6: 1156–61
Sajjan U, Reisman J, Doig P, et al. Binding of nonmucoid Pseudomonas aeruginosa to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest 1992; 89: 657–65
Lam J, Chan R, Lam K, et al. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980; 28: 546–56
Woods DE, Bass JA, Johanson WGJ, et al. Role of adherence in the pathogenesis of Pseudomonas aeruginosa lung infection in cystic fibrosis patients. Infect Immun 1980; 30: 694–9
May TB, Shinabarger D, Maharaj R, et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 1991; 4: 191–206
Kharazmi A. Mechanisms involved in the evasion of the host defence by P. aeruginosa. Immunol Lett 1991; 30: 201–6
Meyer KC, Lewandoski JR, Zimmerman JJ, et al. Human neutrophil elastase and elastase/alphalantiprotease complex in cystic fibrosis. Am Rev Respir Dis 1991; 144: 580–5
Jackowski JT, Szepfalusi Z, Wanner DA, et al. Effects of P. aeruginosa-derived bacterial products on tracheal ciliary function: role of 02radicals. Am J Physiol 1991; 260: L61–L67
Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991; 4: 26–32
Wilson R, Pitt T, Taylor G, et al. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest 1987; 79: 221–9
Speert DP, Dimmick JE, Pier GB, et al. An immunohistological evaluation of Pseudomonas aeruginosa pulmonary infection in two patients with cystic fibrosis. Pediatr Res 1987; 22: 743–7
McFarlane H, Holzel A, Brenchley P, et al. Immune complexes in cystic fibrosis. BMJ 1975; 1: 423–8
Bruce MC, Poncz L, Klinger JD, et al. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985; 132: 529–35
Goldstein W, Doring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 1986; 134: 49–56
Suter S, Schaad UB, Roux L, et al. Granulocyte neutral proteases and pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis 1984; 149: 523–31
Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478–84
Hoiby N, Schiotz PO. Immune complex mediated tissue in the lungs of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand Suppl 1982; 301: 63–73
Morihara K, Tsuzuki H, Oda K. Protease and elastase of Pseudomonas aeruginosa: inactivation of human plasma α1-proteinase inhibitor. Infect Immun 1979; 24: 188–93
O’Connor CM, Gaffney K, Keane J, et al. α1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis 1993; 148: 1665–70
McElvaney, Hubbard RC, Birrer P, et al. Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392–4
McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. J Clin Invest 1992; 90: 1296–301
Hornick DB, Fick RBJ. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. J Clin Invest 1990; 86: 1285–92
Schaad UB, Lang AB, Wedgwood J, et al. Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity. Pediatr Res 1990; 27: 508–13
Cowan RG, Winnie GB. Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis. J Clin Immunol 1993; 13: 359–70
Auerbach HS, Kirkpatrick JA, Williams M, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 9: 686–8
Majure M, Mroueh S, Spock A. Risk factors for the development of posterior subcapsular cataracts in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis treated with corticosteroids. Pediatr Pulmonol 1989; 6: 260–2
Nourshargh S. Mechanisms of neutrophil and eosinophil accumulation in vivo. Am Rev Respir Dis 1993; 148: S60–4
Pantin CFA, Stead RJ, Hodson ME, et al. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax 1986; 41: 14–8
Lapicque F, Muller N, Payan E, et al. Protein binding and stereoselectivity of nonsteroidal antiinflammatory drugs. Clin Pharmacokinet 1993; 25: 115–25
Vanderhoek JY, Bailey JM. Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leukocytes by the anti-inflammatory agent ibuprofen. J Biol Chem 1984; 259: 6752–6
Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Am Rev Respir Dis 1990; 141: 186–92
Sordelli DO, Cerquietti MC, El-Tawil G. Ibuprofen modifies the inflammatory response of the murine lung to P. aeruginosa. Eur J Resp Dis 1985; 67: 118–27
Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993; 342: 465–9
Konstan MW, Hoppel CL, Chai B-L, et al. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 1991; 118: 956–64
Wallace JL, Keenan CM, Gale D, et al. Exacerbation of experimental colitis by nonsteroidal antiinflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992; 102: 18–27
Bjarnason I, Peters TJ. Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview. Gut 1989; 30: 22–8
Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal anti-inflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987; 93: 480–9
Heath AW. Cytokines and infection. Curr Opin Immunol 1990; 2: 380–4
Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Immunol Today 1993; 14: 260–4
Buret A, Dunkley ML, Pang G, et al. Pulmonary immunity to P. aeruginosa in intestinally immunised rats: the role of alveolar macrophages, TNFα, and IL-1α. Infect Immun. In press.
Buret A, Dunkley M, Clancy RL, et al. Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4. Infect Immun 1993; 61: 671–9
Wilmott RW, Kassab JT, Kilian PL, et al. Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections. Am Rev Respir Dis 1990; 142: 365–8
Suter S, Schaad UB, Roux-Lombard P, et al. Relation between tumor necrosis factor-alpha and granulocyte elastase α1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis 1989; 140: 1640–4
Martin TR, Pistorese BP, Chi EY, et al. Effects of leukotriene B4 in the human lung: recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest 1989; 84: 1609–19
Greally P, Hussein MJ, Cook AJ, et al. Sputum tumour necrosis factor-α and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993; 68: 389–92
Pfeffer KD, Huecksteadt TP, Hoidal JR. Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients. Am J Respir Cell Mol Biol 1993; 9: 511–9
Dinarello CA. Role of interleukin-1 and tumor necrosis factor in systemic responses to infection and inflammation. In: Dinarello CA, editor. Secondary role of interleukin-1 and tumor necrosis factor in systemic responses to infection and inflammation. New York: Raven Press, 1992: 211–32
Galve-de Rochemonteix B, Nicod LP, Chicheportiche R, et al. Regulation of interleukin-1ra, interleukin-1α, and interleukin-1β, production by human alveolar macrophages with phorbol myristate acetate, lipopolysaccharide, and interleukin-4. Am J Respir Cell Mol Biol 1993; 8: 160–8
Vannier E, Miller LC, Dinarello CA. Coordinated anti-inflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992; 89: 4076–80
Watson ML, Smith D, Bourne AD, et al. Cytokines contribute to airway dysfunction in antigen challenged guinea pigs: inhibition of airway hyperreactivity, pulmonary eosinophil accumulation, and tumor necrosis factor generation by pretreatment with an interleukin-1 receptor antagonist. Am J Respir Cell Mol Biol 1993; 8: 365–9
Mulligan MS, Jones ML, Vaporciyan AA, et al. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol 1993; 151: 5666–74
Cominelli F, Nast CC, Clark BD, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972–80
Opal SM, Cross AS, Sadoff JC, et al. Efficacy of anti-lipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest 1991; 88: 885–90
van der Meer JWM, Barza M, Wolff SM, et al. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc Natl Acad Sci USA 1988; 85: 1620–3
Ozaki Y, Ohashi T, Minami A, et al. Enhanced resistance of mice to bacterial infection induced by recombinant interleukin-1α. Infect Immun 1987; 55: 1436–40
Pierangeli SS, Sonnenfeld G. Treatment of murine macrophages with murine interferon-gamma and tumor necrosis factor-alpha enhances uptake and intracellular killing of Pseudomonas aeruginosa. Clin Exp Immunol 1993; 93: 165–71
Dean TP, Dai Y, Shute JK, et al. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum and sera of children with cystic fibrosis. Ped Res 1993; 34: 159–61
Rola-Pleszczynski M, Lemaire I. Leukotrienes augment interleukin 1 production by human monocytes. J Immunol 1985; 135: 3958–61
Farina PR, Graham AG, Homon CA, et al. A produg of a 2.6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor. J Pharmacol Exp Ther 1993; 265: 483–9
Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991; 254: 529–33
Dale DC. Granulocyte colony-stimulating factor in infectious diseases. Curr Opin Infect Dis 1993; 6: 369–73
Yasuda H, Ajiki Y, Shimozato T, et al. Therapeutic efficacy of granulocyte colony-stimulating factor alone and in combination with antibiotics against Pseudomonas aeruginosa infections in mice. Infect Immun 1990; 58: 2502–9
Pennington JE, Small GJ. Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. J Infect Dis 1987; 155: 973–8
Collins MS, Tsay GC, Hector RF, et al. Immunoglobulin G: potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo. Rev Infect Dis 1986; 8: S420–S425
Fick RBJ, Naegel GP, Squier SU, et al. Proteins of the cystic fibrosis respiratory tract. J Clin Invest 1984; 74: 236–48
Doring G, Dalhoff A, Vogel O, et al. In vivo activity of proteases of Pseudomonas aeruginosa in a rat model. J Infect Dis 1984; 149: 532–7
Fick RBJ, Baltimore RS, Squier SU, et al. IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis 1985; 151: 589–98
Wallwork JC, McFarlane H. The sIgA system and hypersensitivity in patients with cystic fibrosis. Clin Allergy 1976; 6: 349–58
Winnie GB, Cowan RG, Wade NA. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis. J Pediatr 1989; 114: 309–14
Van Wye JE, Collins MS, Baylor M, et al. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1990; 9: 7–18
Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis — three year results. Arch Dis Child 1984; 59: 1131–4
Wood RE, Pennington JE, Reynolds HY. Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patients. Pediatr Infect Dis 1983; 2: 367–9
Pennington JE, Reynolds HY, Wood RE, et al. Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am J Med 1975; 58: 629–36
Schaad UB, Lang AB, Wedgwood J, et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991; 338: 1236–7
Pier GB, Koles NL, Meluleni G, et al. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of P. aeruginosa serogroup 06. Infect Immun 1994; 62: 1137–43
Cryz SJ, Furer E, Germanier R. Protection against fatal P. aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun 1984; 43: 795–9
Pollak M, Pier GB, Prescott RK. Immunization with P. aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice. Infect Immun 1984; 43: 759–60
Schreiber JR, Pier GB, Grout M, et al. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody. J Infect Dis 1991; 164: 507–14
Schreiber JR, Dahlhauser P. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides. Infect Immun 1994; 62: 308–12
Tao MH, Levy R. Idiotype/granulocyte-macrophage colonystimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755–8
Heath AW, Playfair JHL. Cytokine-antigen vaccines. Nature 1993; 364: 493
Mestecky J, Abraham R, Ogra PL. Common mucosal immune system and strategies for the development of vaccines effective at the mucosal surfaces. In: Ogra PL, Mestecky J, Lamm ME, et al. editors. Handbook of mucosal immunology. San Diego: Academic Press, 1994: 357–85
Cripps AW, Dunkley ML, Clancy RL. Mucosal and systemic immunizations with killed P. aeruginosa protect against acute respiratory infection in rats. Infect Immun 1994; 62: 1427–36
Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188–92
Hubbard RC, McElvaney NG, Birrer P, et al. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992; 326: 812–5
Aitken M, Burke W, McDonald G, et al. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. JAMA 1992; 267: 1947–51
Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199–202
Vaconcellos CA, Allen PG, Wohl ME, et al. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994-263: 969–71
Thomas DA, Myers MA, Wichert B, et al. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 1991; 99: 1268–70
Knowles MR, Stutts MJ, Spock A, et al. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983; 221: 1067–70
Giunta S, Pieri C, Groppa G. Amiloride, a diuretic with in vitro antimicrobial activity. Pharmacol Res Commun 1984; 16: 821–9
Berkow RL, Dodson RW, Kraft AS. Dissociation of human neutrophil activation events by prolonged treatment with amiloride. J Lab Clin Med 1987; 110: 97–105
App EM, King M, Helfesrieder R, et al. Acute and long-term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990; 141: 605–12
Knowles MR, Church NL, William MS, et al. Apilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322: 1189–94
Graham A, Hasani A, Alton EWFW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6: 1243–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buret, A. Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis. Clin. Immunother. 2, 261–277 (1994). https://doi.org/10.1007/BF03258527
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258527